Healthcare (SH:603313) EBSCN·2025-05-11 13:30Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future investment returns [5]. Core Views - The company plans to repurchase shares for employee stock ownership plans, signaling confidence in long-term development [1][2]. - The trend of mattress manufacturing returning to the U.S. continues due to anti-dumping tariffs and trade policies, impacting imports from various countries including China [2][3]. - The company's operational efficiency in U.S. production bases is improving, with profitability achieved in 2024, and the North American market is expected to contribute significantly to profits [3]. - Domestic consumption stimulus policies are being enhanced, and the company is diversifying its sales channels, which is likely to improve its competitiveness and brand influence in the domestic market [3]. - The report forecasts a profit turnaround, with projected net profits of 307 million, 464 million, and 573 million yuan for 2025, 2026, and 2027 respectively, alongside corresponding EPS of 0.54, 0.81, and 1.00 yuan [3][10]. Summary by Sections Share Repurchase - The company intends to repurchase shares worth 0.85 to 1.7 billion yuan at a maximum price of 10.90 yuan per share, which will account for 1.37% to 2.73% of the total share capital [1][2]. Market Trends - The U.S. has implemented multiple rounds of anti-dumping tariffs on mattresses, leading to a significant decrease in imports, with a projected decline of 12.7% and 9.6% in 2023 and 2024 respectively [2]. - The continuation of high anti-dumping tariffs on Chinese mattresses indicates a sustained trend of "de-China" and manufacturing returning to the U.S. [2]. Financial Projections - The report projects revenue growth from 7.976 billion yuan in 2023 to 12.725 billion yuan in 2027, with a compound annual growth rate of approximately 14.33% [10]. - The company is expected to achieve a gross profit margin of around 38.4% by 2027, indicating stable profitability [12]. Profitability and Valuation - The report anticipates a significant increase in net profit margins, with a forecasted return on equity (ROE) of 11.87% by 2027 [12]. - The price-to-earnings (P/E) ratio is projected to decrease from 42 in 2023 to 8 by 2027, suggesting an attractive valuation as earnings improve [13].